TacticScaleWhat Autek China (欧普康视) Does & How It Makes Money (300595.SZ)
Updated October 2026 · reflects Autek China's latest reported financials
Chinese maker of orthokeratology lenses and myopia-control eye care products. The company earns revenue by selling rigid contact lenses and the care solutions used with them, plus myopia-control, vision-training and eye-treatment products.
How Autek China makes money
The company earns revenue by selling rigid contact lenses and the care solutions used with them, plus myopia-control, vision-training and eye-treatment products. It also sells ophthalmic and optometry medical devices in China.
What Autek China does
Autek China Inc., based in Hefei and incorporated in 2000, is an optometry products company focused on rigid contact lenses and the care products that go with them. Beyond lenses, it sells myopia-control products, visual function training products, and treatments for dry eye, eye strain, presbyopia and accommodative insufficiency. It also supplies ophthalmic and optometry medical devices and eye health products, which places it in China's vision care and myopia management market.
Products & services
- Rigid contact lenses (orthokeratology/RGP)
- Rigid lens care solutions
- Myopia control products
- Visual function training products
- Dry eye, eye strain and presbyopia treatment products
- Ophthalmic and optometry medical devices
欧普康视是做什么的？
欧普康视成立于2000年，总部位于安徽合肥，主要从事视光产品及相关配套产品的研发、生产和销售。核心产品为硬性角膜接触镜及其护理产品，同时提供近视控制、视功能训练，以及干眼、视疲劳、老花和调节不足等治疗类产品。 公司还销售眼科和视光医疗器械及眼健康产品，业务覆盖国内视光与近视防控市场。
What is Autek China worth?
On an owner-earnings DCF, Autek China's most-likely value is about ¥11 versus a recent price near ¥10 (6% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~¥5) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Eyebright Medical Technology (Beijing) (688050.SS) · Zhejiang Crystal-Optech (002273.SZ) · Mingyue Optical Lens (301101.SZ) · Aier Eye Hospital (300015.SZ) · Shenyang Xingqi Pharmaceutical (300573.SZ)